M&A Deal Summary

Cosette Pharmaceuticals Acquires Vyleesi

On December 20, 2023, Cosette Pharmaceuticals acquired life science company Vyleesi from Palatin Technologies for 171M USD

Acquisition Highlights
  • This is Cosette Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Cosette Pharmaceuticals’ largest (disclosed) transaction.
  • This is Cosette Pharmaceuticals’ 1st transaction in the United States.

M&A Deal Summary
Date 2023-12-20
Target Vyleesi
Sector Life Science
Buyer(s) Cosette Pharmaceuticals
Sellers(s) Palatin Technologies
Deal Type Divestiture
Deal Value 171M USD

Target

Vyleesi

United States
Vyleesi is a treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cosette Pharmaceuticals

Bridgewater, New Jersey, United States
Category Company
Sector Life Science
DESCRIPTION

Cosette Pharmaceuticals is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette Pharmaceuticals is based in Bridgewater, New Jersey.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
Country (United States) 1 of 1
Year (2023) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-18 Daiichi Sankyo - Eight Branded Products

Tokyo, Japan

Daiichi Sankyo - Eight Branded Products' provides sales and distribution rights in United States.

Buy -

Seller(S) 1

SELLER

Palatin Technologies

Cranbury, New Jersey, United States
Category Company
Founded 1986
Sector Life Science
Employees30
Revenue 4M USD (2024)
DESCRIPTION

Palatin Technologies discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions. Palatin Technologies was incorporated in 1986 and is based in Cranbury, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United States) 1 of 1
Year (2023) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal